AstraZeneca hands off another Amgen-partnered drug in a $1.5B deal with an acquisitive Allergan
AstraZeneca is cashing in more of its R&D chips today, bagging a $250 million upfront and $1.27 billion in milestones for an IL-23 out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
